In today’s recent session, 0.38 million shares of the Seres Therapeutics Inc (NASDAQ:MCRB) have been traded, and its beta is 2.10. Most recently the company’s share price was $0.73, and it changed around -$0.04 or -4.94% from the last close, which brings the market valuation of the company to $124.55M. MCRB at last check was trading at a discount to its 52-week high of $1.53, offering almost -109.59% off that amount. The share price’s 52-week low was $0.54, which indicates that the recent value has risen by an impressive 26.03% since then. We note from Seres Therapeutics Inc’s average daily trading volume that its 10-day average is 2.21 million shares, with the 3-month average coming to 2.64 million.
Seres Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.43. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended MCRB as a Hold, whereas 4 deemed it a Buy, and 2 rated it as Underweight.
Seres Therapeutics Inc (NASDAQ:MCRB) trade information
Instantly MCRB has been showing red trend so far today with a performance of -4.94% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.8266 on recent trading dayincreased the stock’s daily price by 11.69%. The company’s shares are currently down -12.21% year-to-date, but still down -11.37% over the last five days. On the other hand, Seres Therapeutics Inc (NASDAQ:MCRB) is -17.13% down in the 30-day period. We can see from the shorts that 20.44 million shares have been sold at a short interest cover period of 8.34 day(s).
The consensus price target as assigned by Wall Street analysts is $1.25, which translates to bulls needing to increase their stock price by 41.6% from its current value. Analyst projections state that MCRB is forecast to be at a low of $1.25 and a high of $1.25.
Seres Therapeutics Inc (MCRB) estimates and forecasts
Seres Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -40.45 percent over the past six months and at a 57.30% annual growth rate that is well above the industry average of 16.50%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 18.22%.
MCRB Dividends
Seres Therapeutics Inc’s next quarterly earnings report is expected to be released in February.
Seres Therapeutics Inc (NASDAQ:MCRB)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 13.19% of Seres Therapeutics Inc shares, and 37.19% of them are in the hands of institutional investors. The stock currently has a share float of 42.85%. Seres Therapeutics Inc stock is held by 90.0 institutions, with FLAGSHIP PIONEERING INC. being the largest institutional investor. By 2024-06-30, it held 15.8226% of the shares, which is about 23.12 million shares worth $16.73 million.
FMR LLC, with 15.5489% or 22.72 million shares worth $16.44 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Nov 30, 2024 . The former held 6.95 shares worth $5.1 million, making up 4.07% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 4.04 shares worth around $2.96 million, which represents about 2.36% of the total shares outstanding.
